IDH1 and glioma: In conclusion, this meta-analysis provides more strong evidence that IDH1/2 mutations is an independent prognostic factor for patients with different grades of glioma and that IDH1/2 mutations is associated with improved OS and PFS, especially for patients with WHO grade III and grade II-III.